Literature DB >> 10896652

Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.

P Bonfanti, I Faggion, S La Seta Catamancio, M Violin, C Balotta, S Rusconi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10896652      PMCID： PMC89958          DOI： 10.1128/AAC.44.6.1767-1768.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.

Authors:  L Milazzo; S Rusconi; L Testa; S La Seta-Catamancio; M Galazzi; S Kurtagic; P Citterio; M Gianotto; A Grassini; F Adorni; A d'Arminio-Monforte; M Galli; M Moroni
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

2.  Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.

Authors:  S Rusconi; M P De Pasquale; L Milazzo; G Moscatelli; E Bulgheroni; P Citterio; A d'Arminio-Monforte; M Moroni; M Galli
Journal:  Antivir Ther       Date:  1997-01

3.  The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.

Authors:  L Ross; M Johnson; N Graham; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  1999 Sep-Oct

4.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.

Authors:  A K Iversen; R W Shafer; K Wehrly; M A Winters; J I Mullins; B Chesebro; T C Merigan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

Review 5.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Authors:  M S Hirsch; B Conway; R T D'Aquila; V A Johnson; F Brun-Vézinet; B Clotet; L M Demeter; S M Hammer; D M Jacobsen; D R Kuritzkes; C Loveday; J W Mellors; S Vella; D D Richman
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

6.  Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.

Authors:  D P Merrill; M Moonis; T C Chou; M S Hirsch
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

7.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

Authors:  M A Winters; K L Coolley; Y A Girard; D J Levee; H Hamdan; R W Shafer; D A Katzenstein; T C Merigan
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

8.  A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

Authors:  B A Larder; S Bloor; S D Kemp; K Hertogs; R L Desmet; V Miller; M Sturmer; S Staszewski; J Ren; D K Stammers; D I Stuart; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191
  8 in total
  2 in total

1.  Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.

Authors:  Paul L Boyer; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 2.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.

Authors:  Stefan G Sarafianos; Bruno Marchand; Kalyan Das; Daniel M Himmel; Michael A Parniak; Stephen H Hughes; Eddy Arnold
Journal:  J Mol Biol       Date:  2008-11-03       Impact factor: 5.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.